Riskpilot← Back to searchSign inGet full accessPharmaLex Sweden AB
ABActiveOrg 5566471941Mölndalsvägen 30 BBusiness and other management consultancy activities · NACE 7020Est. 200310-19 employees
Revenue 2024
SEK 43,7M
+58% vs 2023
EBITDA margin
3.2%
+236% vs 2023
Equity ratio
27.0%
Financial strength
Net profit 2024
SEK 1,1M
+269% vs 2023
| Revenue | SEK 43,7M | +58% |
| EBITDA | SEK 1,4M | +236% |
| Net profit | SEK 1,1M | +269% |
| Total assets | SEK 13,9M | +40% |
| Equity | SEK 3,7M | +42% |
| Employees | — | — |
Legal name
PharmaLex Sweden AB
Org number
5566471941
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
11 september 2003
Share capital
SEK 100 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Verksamheten ska tillhandahålla konsulttjänster för läkemedels- och medicintekniska industrin samt för hälso- och sjukvården inom produktutveckling, hälsoekonomi, säkerhetsfrågor, regelverk och tillsyn, förvalta värdepapper samt bedriva därmed förenlig verk- samhet.
Address
Mölndalsvägen 30 B
Phone
+46317242201
Email
info.se@pharmalex.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 13 916 | 17 353 | 26 777 | 27 726 | 43 706 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 150 | 1 212 | 2 723 | 416 | 1 398 |
| Depreciation & amort. | −12 | −17 | −17 | −11 | −14 |
| EBIT | 1 138 | 1 195 | 2 706 | 405 | 1 384 |
| Net financials | — | — | — | 5 | −2 |
| Profit before tax | 1 138 | 1 195 | 2 706 | 410 | 1 383 |
| Tax | −248 | −251 | −565 | −108 | −268 |
| Net profit | 890 | 944 | 2 141 | 302 | 1 115 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 7 391 | 7 101 | 9 293 | 9 935 | 13 871 |
| Equity | 2 742 | 1 686 | 3 827 | 2 629 | 3 744 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 649 | 5 415 | 5 466 | 7 306 | 10 127 |
| Total debt | 4 649 | 5 415 | 5 466 | 7 306 | 10 127 |
EBITDA margin
3.2%
This company
15.8%
Market median
-80% vs market
20202024
Equity ratio
27.0%
This company
38.2%
Market median
-29% vs market
20202024
Return on equity
29.8%
This company
18.4%
Market median
+62% vs market
20202024
Net profit margin
2.6%
This company
8.1%
Market median
-68% vs market
20202024
Asset turnover
3.15×
This company
1.12×
Market median
+181% vs market
20202024
Debt / equity
2.70×
This company
0.62×
Market median
-335% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AL Chief Auditor | Chief Auditor | 2025 |
ÅB Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (1) | ||
IL Chief Auditor | Chief Auditor | 2020 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
EE | Chairman | 2025 |
| Board of Directors | 2022 | |
| Former (3) | ||
| Board of Directors | 2020 – 2025 | |
| Board of Directors | 2020 – 2022 | |
| Chairman | 2020 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AMERISOURCEBERGEN INTERNATIONAL B.V
PharmaLex Sweden AB (this company)Board members of PharmaLex Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anton Lars van Dijck | Chief Auditor | 0 companies |
| Åsa Birgitta Pihlblad | Chief Executive Officer | 0 companies |
| Ingvar Lars-Göran Larsson | Chief Auditor | 0 companies |
| Eva Edil | Chairman | 0 companies |
| Christopher Gauglitz | Board of Directors | 0 companies |
| Laurent Maurice Robert Couston | Board of Directors | 0 companies |
| Ann Ingela Nermark Björholt | Board of Directors | 0 companies |
| Torben Thers Norgaard | Chairman | 0 companies |